Hepatitis B Surface Antigen Serum Levels Help to Distinguish Active From Inactive Hepatitis B Virus Genotype D Carriers
Background & Aims
The accurate identification of inactive (serum HBV-DNA persistently ≤2000 IU/mL) hepatitis B virus (HBV) carriers (IC) is difficult because of wide and frequent HBV-DNA fluctuations. We studied whether hepatitis B surface antigen (HBsAg) serum levels (HBsAgsl) quantification may contribute to diagnosis of HBV phases in untreated hepatitis B e antigen-negative genotype D asymptomatic carriers.
Methods
HBsAgsl were measured at baseline and end of follow-up and correlated with virologic and biochemical profiles of 209 consecutive carriers followed-up prospectively (median, 29; range, 12–110 months). HBV phases were defined after 1-year monthly monitoring of HBV-DNA and transaminases.
Results
HBsAgsl were significantly lower in 56 inactive carriers (IC) than 153 active carriers (AC): median, 62.12 (range, 0.1–4068) vs median, 3029 (range, 0.5–82,480) IU/mL; P < .001. Among AC, HBsAgsl were lower in 31 AC whose viremia remained persistently <20,000 IU/mL (AC1) than in 122 AC with fluctuations ≥20,000 IU/mL (AC2): 883 (0.5–7838) vs 4233 (164–82,480) IU/mL, P = .002. HBV infection was less productive in IC and AC1 than AC2 (log10 HBV-DNA/HBsAgsl ratios 0.25 and 0.49 vs 2.06, respectively, P < .001) and in chronic hepatitis than cirrhosis (1.97 vs 2.34, respectively; P = .023). The combined single point quantification of HBsAg (<1000 IU/mL) and HBV-DNA (≤2000 IU/mL) identified IC with 94.3% diagnostic accuracy, 91.1% sensitivity, 95.4% specificity, 87.9% positive predictive value, 96.7% negative predictive value. During follow-up, HBsAgsl were stable in AC but declined in IC (yearly median decline, −0.0120 vs −0.0768 log10 IU/mL, respectively, P < .001), 10 of whom cleared HBsAg.
Conclusions
HBsAgsl vary during chronic hepatitis B e antigen-negative genotype D infection and are significantly lower in IC. Single-point combined HBsAg and HBV-DNA quantification provides the most accurate identification of IC, comparable with that of long-term tight monitoring.
Keywords: HBsAg Quantification, Inactive HBV Infection, HBeAg Negative Chronic Hepatitis B
Abbreviations used in this paper: AC, active carriers, AC1, active carriers with HBV-DNA persistently <20,000 IU/mL, AC2, active carriers with HBV-DNA ≥20,000 IU/mL, ALT, alanine aminotransferase, anti-HBc, antibody to hepatitis B core antigen, anti-HBe, antibody to hepatitis B e antigen, AUROC, area under the receiver operating characteristic, cccDNA, covalently closed circular DNA, DA, diagnostic accuracy, CHB, chronic hepatitis B, HBeAg, hepatitis B e antigen, HBsAg, hepatitis B surface antigen, HBsAgsl, HBsAg serum levels, HBV, hepatitis B virus, IC, inactive carriers, IgM, immunoglobulin M, NPV, negative predictive value, PPV, positive predictive value, ROC, receiver operating characteristic
To access this article, please choose from the options below
Conflicts of interest The authors disclose the following: Maurizia Rossana Brunetto was an invited speaker at meetings sponsored by Abbott. The remaining authors disclose no conflicts.
Funding Supported by an educational grant of the Italian Ministry of Health (“Viral hepatitis emergency: surveillance and management of antiviral resistance to therapy”- n.85 2006); supply of reagents for the laboratory activity; part-time fellowship for a biologist.
PII: S0016-5085(10)00660-8
doi:10.1053/j.gastro.2010.04.052
© 2010 AGA Institute. Published by Elsevier Inc. All rights reserved.

